Last reviewed · How we verify
Luveris®
Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroid production and follicle development in women undergoing fertility treatment.
Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroidogenesis and follicle development in women undergoing assisted reproductive technology. Used for Infertility in women with profound LH deficiency undergoing assisted reproductive technology, Ovulation induction in combination with FSH in hypogonadotropic hypogonadal women.
At a glance
| Generic name | Luveris® |
|---|---|
| Also known as | Gonal-f, ovidrel |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Gonadotropin; recombinant luteinizing hormone |
| Target | Luteinizing hormone receptor (LHCG receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive endocrinology; Fertility |
| Phase | FDA-approved |
Mechanism of action
Luveris binds to LH receptors on ovarian theca cells, stimulating androgen production which is then converted to estrogen by granulosa cells. This hormone replacement therapy is used in combination with follicle-stimulating hormone (FSH) to support controlled ovarian hyperstimulation in assisted reproductive technology cycles, particularly in women with LH deficiency or hypogonadotropic hypogonadism.
Approved indications
- Infertility in women with profound LH deficiency undergoing assisted reproductive technology
- Anovulation in women with hypogonadotropic hypogonadism
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Abdominal pain
- Injection site reactions
- Nausea
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment (PHASE4)
- PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PHASE3)
- A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
- Lutropin Alfa in Women at Risk of Poor Response (PHASE2)
- The Luveris In Vitro Fertilization Trial (PHASE4)
- Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (PHASE3)
- A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Luveris® CI brief — competitive landscape report
- Luveris® updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI